Clinical Trial Search

Primary: Incidence And Severity Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 13; 5; 7; 7 Participants

Primary: Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions — 1.03; 1.39; 0.77; 0.76 lesions — p=0.1673

Primary: NAb Dose Titer in the Convalescent Plasma (CP), Pre-treatment, and Day One in Hospitalized Patients With Documented COVID-19 Infection — 56.7; 390; 413 titer

Primary: Maximum-tolerated Dose of MLN9708. — 4 millligram

Primary: Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase — 0; 0; 0 Participants

Primary: Pre-metastatic Niche Density — 75.6; 62.5 clusters/hpf — p=>0.05

Primary: Overall Survival as Measured by Number of Participants Alive Through 28 Days — 10; 8 Participants

Primary: Brain Penetrance of Dasatinib (D) — 0.27 ng/ml

Primary: Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths — 4; 6; 4; 6 Participants

Primary: Number of Unscheduled Healthcare Visits (UHCV) — 0.5; 0.5 number of visits — p=0.05

Primary: Change in Pulmonary Vascular Resistance (PVR) — 73.1; 46.6 dyn.sec/cm5

Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…

Primary: Change in Sputum Bacterial Culture — -0.59; -0.89 CFU/mL

Primary: Objective Response Rate (ORR) — 1; 1 Participants

Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg